The phase III MARIPOSA-2 study strengthens the case for amivantamab: in EGFR-mutated advanced NSCLC after progression on osimertinib, both amivantamab monotherapy and amivantamab–lazertinib significantly prolonged PFS compared to chemotherapy (6.3 and 8.3 vs. 4.2 months; p < 0.001) [303]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.